How Analysts Feel About MATEON THERAPEUTICS INCORPORATED (OTCMKTS:MATN) After Increase in Sellers?

February 15, 2018 - By Kurt Siggers

The stock of MATEON THERAPEUTICS INCORPORATED (OTCMKTS:MATN) registered an increase of 4.29% in short interest. MATN’s total short interest was 7,300 shares in February as published by FINRA. Its up 4.29% from 7,000 shares, reported previously. With 100,000 shares average volume, it will take short sellers 0 days to cover their MATN’s short positions.

The stock increased 15.05% or $0.0301 during the last trading session, reaching $0.2301. About 78,163 shares traded. Mateon Therapeutics, Inc. (OTCMKTS:MATN) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Mateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. The company has market cap of $6.11 million. The Company’s principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. It currently has negative earnings. The firm also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes.

More notable recent Mateon Therapeutics, Inc. (OTCMKTS:MATN) news were published by: which released: “Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P …” on August 16, 2017, also with their article: “Mateon Therapeutics Announces Abstract Presentations for the American …” published on March 31, 2017, published: “Mateon Therapeutics to Present at the 2018 Biotech Showcase” on January 03, 2018. More interesting news about Mateon Therapeutics, Inc. (OTCMKTS:MATN) were released by: and their article: “Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study …” published on October 30, 2017 as well as‘s news article titled: “Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and …” with publication date: September 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.